IMPROVING HEPATOCYTE BIOMARKERS VALUESWITH CONTINUOUS ENERGO-METABOLIC THERAPY IN POST MYOCARDIAL INFARCTION PATIENTS TREATEDWITH STATINS
Abstract:
Background. Current guidelines recommend statins post myocardial infarction (MI). The energo-metabolic agent trimetazidine is prescribed in this setting according to the physicians’ decision related to co-morbidities, taking into consideration its proven beneficial effects in angina and heart failure. Goal. To test the hypothesis that continuous energo-metabolic therapy (CEMT) with trimetazidine could improve aminotransferase values in post-MI pts treated with high-dose statin. Method. We analysed retrospectively 01/01/08-31/12/12 a number of 1008 pts > 18 yrs old, newly diagnosed with ST elevation MI (relevant ECG + biomarkers) who underwent statin therapy in high dosages (atorvastatin 80 mg or rosuvastatin 40 mg). We selected 874 = 288 x 3 = 288 CEMT + 576 non-CEMT pts who remained on these dosages at least 12 months. The aminotransferase assessment was performed at 3, 6, 12 and 24 months. Results. After propensity matching (1:2), the 288 pts receiving CEMT were combined with 576 controls. The number of aminotransferase elevations was considerably lower in pts receiving CEMT than in controls. Conclusion. According to our results, CEMT could act quite similarly in hepatocyte as in myocardial cell, at mithochondrial level. However, a well organized study on this topic is warranted.
full text article in Romanian (.RO) |
full text article in English (.EN) |